| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.18 | 0.002 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |